The comparative in vitro potency of XRP2868, a new oral semisynthetic streptogramin antibiotic, was evaluated against gram-positive bacteria. XRP2868 inhibited all staphylococci at < or = 1 microg/ml and all non-pneumococcal streptococci at < or = 0.25 microg/ml and was fourfold more potent than quinupristin-dalfopristin against Staphylococcus aureus and Enterococcus faecium.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1168641 | PMC |
| http://dx.doi.org/10.1128/AAC.49.7.3034-3039.2005 | DOI Listing |
Publication Analysis
Top Keywords
gram-positive bacteria
8
vitro activity
4
activity oral
4
oral streptogramin
4
streptogramin antimicrobial
4
antimicrobial xrp2868
4
xrp2868 gram-positive
4
bacteria comparative
4
comparative vitro
4
vitro potency
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!